BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 2017;19:69-76. [PMID: 27388693 DOI: 10.1038/gim.2016.80] [Cited by in Crossref: 221] [Cited by in F6Publishing: 197] [Article Influence: 36.8] [Reference Citation Analysis]
Number Citing Articles
1 Thorén L, Eriksson M, Lindh JD, Czene K, Bergh J, Eliasson E, Hall P, Margolin S. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. Breast Cancer Res Treat 2021;190:451-62. [PMID: 34570302 DOI: 10.1007/s10549-021-06386-2] [Reference Citation Analysis]
2 Tang S, Zhao P, Zheng L, Wen C, Wang L, Jiang X. Impacts of Cytochrome P450 2D6*10 Allele and a High-Fat Meal on the Pharmacokinetics of Dapoxetine in Healthy Chinese Men: A Single-Dose, Two-Treatment Study. Adv Ther 2019;36:2096-105. [DOI: 10.1007/s12325-019-00982-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Eapen-John D, Mohiuddin AG, Kennedy JL. A Potential Paradigm Shift in Opioid Crisis Management: The Role of Pharmacogenomics. World J Biol Psychiatry 2021;:1-19. [PMID: 34854362 DOI: 10.1080/15622975.2021.2012397] [Reference Citation Analysis]
4 Park YA, Park KH, Yoon HY, Yee J, Gwak HS. Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis. Travel Med Infect Dis 2022;:102333. [PMID: 35452835 DOI: 10.1016/j.tmaid.2022.102333] [Reference Citation Analysis]
5 Lee SM, Park Y, Kim YJ, Hwang HS, Seo H, Min BJ, Lee KH, Kim SY, Jung YM, Lee S, Park CW, Kim JH, Park JS. Identifying genetic variants associated with ritodrine-induced pulmonary edema. PLoS One 2020;15:e0241215. [PMID: 33166306 DOI: 10.1371/journal.pone.0241215] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Wendt FR, Sajantila A, Moura-neto RS, Woerner AE, Budowle B. Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences. Int J Legal Med 2018;132:1007-24. [DOI: 10.1007/s00414-017-1709-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
7 Oshikoya KA, Neely KM, Carroll RJ, Aka IT, Maxwell-Horn AC, Roden DM, Van Driest SL. CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res 2019;85:602-6. [PMID: 30661084 DOI: 10.1038/s41390-019-0305-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
8 Zhang H, De T, Zhong Y, Perera MA. The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation? Clin Pharmacol Ther 2019;106:338-49. [PMID: 31038731 DOI: 10.1002/cpt.1491] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
9 Shah RR, Gaedigk A. Precision medicine: does ethnicity information complement genotype-based prescribing decisions? Ther Adv Drug Saf 2018;9:45-62. [PMID: 29318005 DOI: 10.1177/2042098617743393] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
10 McInnes G, Dalton R, Sangkuhl K, Whirl-Carrillo M, Lee SB, Tsao PS, Gaedigk A, Altman RB, Woodahl EL. Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Comput Biol 2020;16:e1008399. [PMID: 33137098 DOI: 10.1371/journal.pcbi.1008399] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Twesigomwe D, Wright GEB, Drögemöller BI, da Rocha J, Lombard Z, Hazelhurst S. A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on CYP2D6 genotyping. NPJ Genom Med 2020;5:30. [PMID: 32789024 DOI: 10.1038/s41525-020-0135-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
12 Mutawi TM, Zedan MM, Yahya RS, Zakria MM, El-Sawi MR, Gaedigk A. Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population. Pharmacogenomics 2021;22:323-34. [PMID: 33789449 DOI: 10.2217/pgs-2020-0140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sarhan SA, Sherby NA, Raafat N, Alian SM. Association of cytochrome P2D6 gene polymorphism with the susceptibility of Egyptian patients to systemic sclerosis disease. Meta Gene 2021;29:100926. [DOI: 10.1016/j.mgene.2021.100926] [Reference Citation Analysis]
14 Rodieux F, Vutskits L, Posfay-Barbe KM, Habre W, Piguet V, Desmeules JA, Samer CF. When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children. Front Pharmacol 2018;9:148. [PMID: 29556194 DOI: 10.3389/fphar.2018.00148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
15 Lin YS, Thummel KE, Thompson BD, Totah RA, Cho CW. Sources of Interindividual Variability. Methods Mol Biol 2021;2342:481-550. [PMID: 34272705 DOI: 10.1007/978-1-0716-1554-6_17] [Reference Citation Analysis]
16 Aklillu E, Engidawork E. The impact of catha edulis (vahl) forssk. ex endl. (celestraceae) (khat) on pharmacokinetics of clinically used drugs. Expert Opin Drug Metab Toxicol 2021;17:1125-38. [PMID: 34410209 DOI: 10.1080/17425255.2021.1971194] [Reference Citation Analysis]
17 Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen SLW, Mathijssen RHJ, Joerger M, Kloft C. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. Front Pharmacol 2020;11:283. [PMID: 32296331 DOI: 10.3389/fphar.2020.00283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
18 Zhou Y, Lauschke VM. Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. J Med Genet 2018;55:617-27. [PMID: 29970487 DOI: 10.1136/jmedgenet-2018-105429] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
19 Mehlotra RK, Gaedigk A, Howes RE, Rakotomanga TA, Ratsimbasoa AC, Zimmerman PA. CYP2D6 Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar. Front Pharmacol 2021;12:654054. [PMID: 33959023 DOI: 10.3389/fphar.2021.654054] [Reference Citation Analysis]
20 Lee SB, Wheeler MM, Thummel KE, Nickerson DA. Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. Clin Pharmacol Ther 2019;106:1328-37. [PMID: 31206625 DOI: 10.1002/cpt.1552] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
21 Koller D, Belmonte C, Lubomirov R, Saiz-rodríguez M, Zubiaur P, Román M, Ochoa D, Carcas A, Wojnicz A, Abad-santos F. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. J Psychopharmacol 2018;32:1212-22. [DOI: 10.1177/0269881118798605] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Fukunaga K, Hishinuma E, Hiratsuka M, Kato K, Okusaka T, Saito T, Ikeda M, Yoshida T, Zembutsu H, Iwata N, Mushiroda T. Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population. J Hum Genet 2021;66:139-49. [PMID: 32759992 DOI: 10.1038/s10038-020-0815-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Qian JC, Cai JP, Hu GX. Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties. Expert Opin Drug Metab Toxicol 2021;17:707-16. [PMID: 33910442 DOI: 10.1080/17425255.2021.1921147] [Reference Citation Analysis]
24 [DOI: 10.1101/684357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Frederiksen T, Areberg J, Schmidt E, Stage TB, Brøsen K. Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 33932135 DOI: 10.1002/psp4.12635] [Reference Citation Analysis]
26 Chen N, Dowd S, Gatton ML, Auliff A, Edstein MD, Cheng Q. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor. Malar J 2019;18:140. [PMID: 30999967 DOI: 10.1186/s12936-019-2774-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
27 Qiao W, Martis S, Mendiratta G, Shi L, Botton MR, Yang Y, Gaedigk A, Vijzelaar R, Edelmann L, Kornreich R, Desnick RJ, Scott SA. Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection. Pharmacogenomics 2019;20:9-20. [PMID: 30730286 DOI: 10.2217/pgs-2018-0135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Zai CC, Maes MS, Tiwari AK, Zai GC, Remington G, Kennedy JL. Genetics of tardive dyskinesia: Promising leads and ways forward. J Neurol Sci. 2018;389:28-34. [PMID: 29502799 DOI: 10.1016/j.jns.2018.02.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
29 Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, Frean J, Wiesner L, Barnes KI. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J 2019;18:209. [PMID: 31234865 DOI: 10.1186/s12936-019-2841-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
30 Eliasen A, Dalhoff K, Mathiasen R, Schmiegelow K, Rechnitzer C, Schelde AB, Perwitasari DA, Tsuji D, Brok J. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2020;149:102939. [PMID: 32259776 DOI: 10.1016/j.critrevonc.2020.102939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
31 Amaeze O, Eng H, Horlbogen L, Varma MVS, Slitt A. Cytochrome P450 Enzyme Inhibition and Herb-Drug Interaction Potential of Medicinal Plant Extracts Used for Management of Diabetes in Nigeria. Eur J Drug Metab Pharmacokinet 2021;46:437-50. [PMID: 33844145 DOI: 10.1007/s13318-021-00685-1] [Reference Citation Analysis]
32 Gajendran M, Sarosiek I, McCallum R. Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. Expert Rev Endocrinol Metab 2021;16:25-35. [PMID: 33739209 DOI: 10.1080/17446651.2021.1886922] [Reference Citation Analysis]
33 Huebner T, Steffens M, Linder R, Fracowiak J, Langner D, Garling M, Falkenberg F, Roethlein C, Gomm W, Haenisch B, Stingl J. Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR. BMJ Open 2020;10:e032624. [PMID: 32345696 DOI: 10.1136/bmjopen-2019-032624] [Reference Citation Analysis]
34 B Tata E, A Ambele M, S Pepper M. Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review. Pharmaceutics 2020;12:E809. [PMID: 32858798 DOI: 10.3390/pharmaceutics12090809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Liutkeviciene R, Vilkeviciute A, Gedvilaite G, Kaikaryte K, Kriauciuniene L. Haplotypes of HTRA1 rs1120638, TIMP3 rs9621532, VEGFA rs833068, CFI rs10033900, ERCC6 rs3793784, and KCTD10 rs56209061 Gene Polymorphisms in Age-Related Macular Degeneration. Dis Markers 2019;2019:9602949. [PMID: 31583032 DOI: 10.1155/2019/9602949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Tornio A, Backman JT. Cytochrome P450 in Pharmacogenetics: An Update. Adv Pharmacol 2018;83:3-32. [PMID: 29801580 DOI: 10.1016/bs.apha.2018.04.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
37 Larsen JB, Rasmussen JB. Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19. Pharmgenomics Pers Med 2017;10:115-28. [PMID: 28458572 DOI: 10.2147/PGPM.S131580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Zanger UM, Momoi K, Hofmann U, Schwab M, Klein K. Tri-Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41. Clin Pharmacol Ther 2021;109:1256-64. [PMID: 33043448 DOI: 10.1002/cpt.2078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Stojanović Marković A, Zajc Petranović M, Tomas Ž, Puljko B, Šetinc M, Škarić-jurić T, Peričić Salihović M. Untangling SNP Variations within CYP2D6 Gene in Croatian Roma. JPM 2022;12:374. [DOI: 10.3390/jpm12030374] [Reference Citation Analysis]
40 Rocco R, Thiels CA, Ubl DS, Moyer AM, Habermann EB, Cassivi SD. Use of pharmacogenetic data to guide individualized opioid prescribing after surgery. Surgery 2019;166:476-82. [PMID: 31320226 DOI: 10.1016/j.surg.2019.04.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Malafoglia V, Tenti M, Ilari S, Balzani E, Fanelli A, Muscoli C, Raffaeli W, Bonci A. Opportunities and challenges for nonaddictive interventions in chronic pain. Curr Opin Pharmacol 2021;57:184-91. [PMID: 33799001 DOI: 10.1016/j.coph.2021.02.007] [Reference Citation Analysis]
42 Sukasem C, Vanwong N, Srisawasdi P, Ngamsamut N, Nuntamool N, Hongkaew Y, Puangpetch A, Chamkrachangpada B, Limsila P. Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. Basic Clin Pharmacol Toxicol 2018;123:42-50. [DOI: 10.1111/bcpt.12970] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
43 Won DY, Byun SJ, Jeong JS, Shin JY. Association Between Acetylcholinesterase Inhibitors and Osteoporotic Fractures in Older Persons With Alzheimer's Disease. J Am Med Dir Assoc 2020;21:1128-1133.e1. [PMID: 31926798 DOI: 10.1016/j.jamda.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
44 de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology. 2019;Online ahead of print. [PMID: 31150659 DOI: 10.1016/j.neuropharm.2019.05.033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
45 Chamnanphon M, Wainipitapong S, Wiwattarangkul T, Chuchuen P, Nissaipan K, Phaisal W, Tangwongchai S, Sukasem C, Wittayalertpanya S, Gaedigk A, Aniwattanapong D, Chariyavilaskul P. CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia. Pharmgenomics Pers Med 2020;13:543-51. [PMID: 33177862 DOI: 10.2147/PGPM.S276230] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Ruaño G, Tortora J, Robinson S, Baker S, Holford T, Winokur A, Goethe JW. Subanalysis of the CYP-GUIDES Trial: CYP2D6 Functional Stratification and Operational Timeline Selection. Psychiatry Res 2021;297:113571. [PMID: 33513485 DOI: 10.1016/j.psychres.2020.113571] [Reference Citation Analysis]
47 Cirnigliaro G, Di Bernardo I, Caricasole V, Piccoli E, Scaramelli B, Pomati S, Villa C, Pantoni L, Dell'Osso B. Treatment-related transient splenial lesion of the Corpus Callosum in patients with neuropsychiatric disorders: a literature overview with a case report. Expert Opin Drug Saf 2020;19:315-25. [PMID: 32063066 DOI: 10.1080/14740338.2020.1731472] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Kam H, Jeong H. Pharmacogenomic Biomarkers and Their Applications in Psychiatry. Genes (Basel) 2020;11:E1445. [PMID: 33266292 DOI: 10.3390/genes11121445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Fernandez-Miñope C, Delgado-Ratto C, Contreras-Mancilla J, Ferrucci HR, Llanos-Cuentas A, Gamboa D, Van Geertruyden JP. Towards one standard treatment for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria: Perspectives from and for the Peruvian Amazon. Int J Infect Dis 2021;105:293-7. [PMID: 33596478 DOI: 10.1016/j.ijid.2021.02.042] [Reference Citation Analysis]
50 Ma L, Xiang Q, Zhao N, Hu C, Fang M, Tan Y, Chen S, Wang Z, Liu P, Sun K, Li Y, Wu F, Tian H, Fang M, Zhao X, Wang G, Cui Y. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations. Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110241. [PMID: 33400943 DOI: 10.1016/j.pnpbp.2020.110241] [Reference Citation Analysis]
51 Takahashi PY, Ryu E, Bielinski SJ, Hathcock M, Jenkins GD, Cerhan JR, Olson JE. No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study. Pharmgenomics Pers Med 2021;14:229-37. [PMID: 33603442 DOI: 10.2147/PGPM.S281645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
52 Pan X, Ning M, Jeong H. Transcriptional Regulation of CYP2D6 Expression. Drug Metab Dispos 2017;45:42-8. [PMID: 27698228 DOI: 10.1124/dmd.116.072249] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
53 Kim EY, Shin SG, Shin JG. Prediction and visualization of CYP2D6 genotype-based phenotype using clustering algorithms. Transl Clin Pharmacol 2017;25:147-52. [PMID: 32095466 DOI: 10.12793/tcp.2017.25.3.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Caré W, Tangre A, Dufayet L, Lekens B, Laborde-Casterot H, Langrand J, Mégarbane B, Vodovar D; French Poison Centers Research Network. Exposure to immediate-release tramadol in children 6 years and under - a nationwide French poison control center study. Clin Toxicol (Phila) 2022;:1-9. [PMID: 35179098 DOI: 10.1080/15563650.2022.2033257] [Reference Citation Analysis]
55 Smith DM, Weitzel KW, Cavallari LH, Elsey AR, Schmidt SO. Clinical application of pharmacogenetics in pain management. Per Med 2018;15:117-26. [PMID: 29714124 DOI: 10.2217/pme-2017-0032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
56 Singh A, Zai C, Mohiuddin AG, Kennedy JL. The pharmacogenetics of opioid treatment for pain management. J Psychopharmacol 2020;34:1200-9. [DOI: 10.1177/0269881120944162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
57 Indorf P, Patzak A, Lichtenberger FB. Drug metabolism in animal models and humans: Translational aspects and chances for individual therapy. Acta Physiol (Oxf) 2021;233:e13734. [PMID: 34637592 DOI: 10.1111/apha.13734] [Reference Citation Analysis]
58 Koopmans AB, Braakman MH, Vinkers DJ, Hoek HW, van Harten PN. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry 2021;11:141. [PMID: 33627619 DOI: 10.1038/s41398-020-01129-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhang X, Xiang Q, Zhao X, Ma L, Cui Y. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis. J Clin Pharm Ther 2019;44:163-73. [DOI: 10.1111/jcpt.12780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
60 Maruf AA, Fan M, Arnold PD, Müller DJ, Aitchison KJ, Bousman CA. Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can J Psychiatry 2020;65:521-30. [PMID: 32064906 DOI: 10.1177/0706743720904820] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
61 Leitão LPC, Souza TP, Rodrigues JCG, Fernandes MR, Santos S, Santos NPC. The Metabolization Profile of the CYP2D6 Gene in Amerindian Populations: A Review. Genes (Basel) 2020;11:E262. [PMID: 32121156 DOI: 10.3390/genes11030262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Khojasteh SC, Miller GP, Mitra K, Rietjens IMCM. Biotransformation and bioactivation reactions - 2017 literature highlights *. Drug Metab Rev 2018;50:221-55. [PMID: 29954222 DOI: 10.1080/03602532.2018.1473875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Rajman I, Knapp L, Morgan T, Masimirembwa C. African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine 2017;17:67-74. [PMID: 28237373 DOI: 10.1016/j.ebiom.2017.02.017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
64 Wong YC, Centanni M, de Lange ECM. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human. J Clin Pharmacol 2019;59:731-47. [PMID: 30676661 DOI: 10.1002/jcph.1365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
65 Skadrić I, Stojković O. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. Int J Legal Med 2020;134:433-9. [PMID: 31858263 DOI: 10.1007/s00414-019-02234-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
66 Wendt FR, Novroski NMM, Rahikainen AL, Sajantila A, Budowle B. A pathway-driven predictive model of tramadol pharmacogenetics. Eur J Hum Genet 2019;27:1143-56. [PMID: 30824817 DOI: 10.1038/s41431-019-0369-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
67 Hoshitsuki K, Crews KR, Yang W, Smith CA, Hankins JS, Turner AJ, Broeckel U, McMillin GA, Relling MV, Haidar CE. Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination. Genet Med 2020;22:232-3. [PMID: 31341243 DOI: 10.1038/s41436-019-0614-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Rollinson V, Turner R, Pirmohamed M. Pharmacogenomics for Primary Care: An Overview. Genes (Basel) 2020;11:E1337. [PMID: 33198260 DOI: 10.3390/genes11111337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Nakamura T, Toshimoto K, Lee W, Imamura CK, Tanigawara Y, Sugiyama Y. Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen. CPT Pharmacometrics Syst Pharmacol 2018;7:474-82. [PMID: 29920987 DOI: 10.1002/psp4.12307] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS One 2017;12:e0170905. [PMID: 28151991 DOI: 10.1371/journal.pone.0170905] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 15.2] [Reference Citation Analysis]
71 Lu JY, Tiwari AK, Freeman N, Zai GC, Luca V, Müller DJ, Tampakeras M, Herbert D, Emmerson H, Cheema SY, King N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL, Zai CC. Liver enzyme CYP2D6 gene and tardive dyskinesia. Pharmacogenomics 2020;21:1065-72. [PMID: 32969762 DOI: 10.2217/pgs-2020-0065] [Reference Citation Analysis]
72 Waring RH. Cytochrome P450: genotype to phenotype. Xenobiotica 2020;50:9-18. [PMID: 31411087 DOI: 10.1080/00498254.2019.1648911] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
73 Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY. Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 2019;42:182-90. [PMID: 30542809 DOI: 10.1007/s12272-018-1099-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
74 Chen R, Zheng X, Hu P. CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D610 on Interindividual Variation in a Chinese Population. Front Pharmacol 2017;8:239. [PMID: 28512430 DOI: 10.3389/fphar.2017.00239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Huff HC, Vasan A, Roy P, Kaul A, Tajkhorshid E, Das A. Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms. Biochemistry 2021;60:2749-60. [PMID: 34491040 DOI: 10.1021/acs.biochem.1c00158] [Reference Citation Analysis]
76 Tay EMY, Roberts DM. A spotlight on the role, use, and availability of codeine and the implications faced. Expert Rev Clin Pharmacol 2018;11:1057-9. [PMID: 30336710 DOI: 10.1080/17512433.2018.1537122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
77 Chen X, Shen F, Gonzaludo N, Malhotra A, Rogert C, Taft RJ, Bentley DR, Eberle MA. Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data. Pharmacogenomics J 2021;21:251-61. [PMID: 33462347 DOI: 10.1038/s41397-020-00205-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
78 Kaye AD, Garcia AJ, Hall OM, Jeha GM, Cramer KD, Granier AL, Kallurkar A, Cornett EM, Urman RD. Update on the pharmacogenomics of pain management. Pharmgenomics Pers Med 2019;12:125-43. [PMID: 31308726 DOI: 10.2147/PGPM.S179152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
79 Nofziger C, Paulmichl M. Accurately genotyping CYP2D6: not for the faint of heart. Pharmacogenomics 2018;19:999-1002. [PMID: 30020016 DOI: 10.2217/pgs-2018-0105] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
80 Jürgens G, Andersen SE, Rasmussen HB, Werge T, Jensen HD, Kaas-Hansen BS, Nordentoft M. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial. JAMA Netw Open 2020;3:e2027909. [PMID: 33284338 DOI: 10.1001/jamanetworkopen.2020.27909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Wendt FR, Novroski NM, Rahikainen A, Sajantila A, Budowle B. Supervised Classification of CYP2D6 Genotype and Metabolizer Phenotype With Postmortem Tramadol-Exposed Finns. Am J Forensic Med Pathol 2019;40:8-18. [DOI: 10.1097/paf.0000000000000447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
82 Pavez Loriè E, Baatout S, Choukér A, Buchheim JI, Baselet B, Dello Russo C, Wotring V, Monici M, Morbidelli L, Gagliardi D, Stingl JC, Surdo L, Yip VLM. The Future of Personalized Medicine in Space: From Observations to Countermeasures. Front Bioeng Biotechnol 2021;9:739747. [PMID: 34966726 DOI: 10.3389/fbioe.2021.739747] [Reference Citation Analysis]
83 Del Tredici AL, Malhotra A, Dedek M, Espin F, Roach D, Zhu GD, Voland J, Moreno TA. Frequency of CYP2D6 Alleles Including Structural Variants in the United States. Front Pharmacol 2018;9:305. [PMID: 29674966 DOI: 10.3389/fphar.2018.00305] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
84 Wendt FR, Rahikainen AL, King JL, Sajantila A, Budowle B. A genome-wide association study of tramadol metabolism from post-mortem samples. Pharmacogenomics J 2020;20:94-103. [PMID: 30971809 DOI: 10.1038/s41397-019-0088-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Ryu S, Park S, Lee JH, Kim YR, Na HS, Lim HS, Choi HY, Hwang IY, Lee JG, Park ZW, Oh WY, Kim JM, Choi SE. A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans. Clin Transl Sci 2017;10:93-101. [PMID: 28296334 DOI: 10.1111/cts.12451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
86 Kaye AD, Mahakian T, Kaye AJ, Pham AA, Hart BM, Gennuso S, Cornett EM, Gabriel RA, Urman RD. Pharmacogenomics, precision medicine, and implications for anesthesia care. Best Practice & Research Clinical Anaesthesiology 2018;32:61-81. [DOI: 10.1016/j.bpa.2018.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
87 Lee SB, Wheeler MM, Patterson K, McGee S, Dalton R, Woodahl EL, Gaedigk A, Thummel KE, Nickerson DA. Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet Med 2019;21:361-72. [PMID: 29875422 DOI: 10.1038/s41436-018-0054-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
88 Chan W, Li MS, Sundaram SK, Tomlinson B, Cheung PY, Tzang CH. CYP2D6 allele frequencies, copy number variants, and tandems in the population of Hong Kong. J Clin Lab Anal 2019;33:e22634. [PMID: 30069923 DOI: 10.1002/jcla.22634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
89 Baird JK. Management of Plasmodium vivax risk and illness in travelers. Trop Dis Travel Med Vaccines 2017;3:7. [PMID: 28883977 DOI: 10.1186/s40794-017-0049-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
90 Rahikainen AL, Vauhkonen P, Pett H, Palo JU, Haukka J, Ojanperä I, Niemi M, Sajantila A. Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions. Int J Legal Med 2019;133:353-63. [PMID: 30173302 DOI: 10.1007/s00414-018-1927-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
91 Russell LE, Zhou Y, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. Pharmacogenomics in the era of next generation sequencing - from byte to bedside. Drug Metab Rev 2021;53:253-78. [PMID: 33820459 DOI: 10.1080/03602532.2021.1909613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Daher A, Aljayyoussi G, Pereira D, Lacerda MVG, Alexandre MAA, Nascimento CT, Alves JC, da Fonseca LB, da Silva DMD, Pinto DP, Rodrigues DF, Silvino ACR, de Sousa TN, de Brito CFA, Ter Kuile FO, Lalloo DG. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine. Malar J 2019;18:325. [PMID: 31547827 DOI: 10.1186/s12936-019-2950-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
93 Vichi S, Buratti FM, Di Consiglio E, Turco L, S Lautz L, Darney K, Dorne JCM, Testai E. OpenCYP: An open source database exploring human variability in activities and frequencies of polymophisms for major cytochrome P-450 isoforms across world populations. Toxicol Lett 2021;350:267-82. [PMID: 34352333 DOI: 10.1016/j.toxlet.2021.07.019] [Reference Citation Analysis]
94 Boone EC, Wang WY, Gaedigk R, Cherner M, Bérard A, Leeder JS, Miller NA, Gaedigk A. Long-Distance Phasing of a Tentative "Enhancer" Single-Nucleotide Polymorphism With CYP2D6 Star Allele Definitions. Front Pharmacol 2020;11:486. [PMID: 32457600 DOI: 10.3389/fphar.2020.00486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
95 Gonçalves BP, Pett H, Tiono AB, Murry D, Sirima SB, Niemi M, Bousema T, Drakeley C, Ter Heine R. Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children. Antimicrob Agents Chemother 2017;61:e02590-16. [PMID: 28289025 DOI: 10.1128/AAC.02590-16] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
96 Kaddurah-Daouk R, Hankemeier T, Scholl EH, Baillie R, Harms A, Stage C, Dalhoff KP, Jűrgens G, Taboureau O, Nzabonimpa GS, Motsinger-Reif AA, Thomsen R, Linnet K, Rasmussen HB; INDICES Consortium., Pharmacometabolomics Research Network. Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. CPT Pharmacometrics Syst Pharmacol 2018;7:525-33. [PMID: 30169917 DOI: 10.1002/psp4.12309] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
97 Wendt FR, Koller D, Pathak GA, Jacoby D, Miller EJ, Polimanti R. Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. Clin Pharmacol Ther 2021;110:777-85. [PMID: 33837531 DOI: 10.1002/cpt.2260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Carano F, Sarno S, De Fanti S, Serventi P, Bini C, Luiselli D, Pelotti S. Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula. Ann Hum Biol 2018;45:66-71. [PMID: 28971704 DOI: 10.1080/03014460.2017.1378368] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
99 Mostafa S, Kirkpatrick CMJ, Byron K, Sheffield L. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. J Neural Transm 2019;126:5-18. [DOI: 10.1007/s00702-018-1922-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
100 Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinb) 2019;116S:S66-70. [PMID: 31076322 DOI: 10.1016/j.tube.2019.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
101 Donath F, Hoffmann L, Todorova-Sanjari M, Wedemeyer RS, Warnke A, Nickisch K. Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. Clin Pharmacol Drug Dev 2021. [PMID: 34101369 DOI: 10.1002/cpdd.968] [Reference Citation Analysis]
102 Thienemann M, Park M, Chan A, Frankovich J. Patients with abrupt early-onset OCD due to PANS tolerate lower doses of antidepressants and antipsychotics. J Psychiatr Res 2021;135:270-8. [PMID: 33513473 DOI: 10.1016/j.jpsychires.2021.01.022] [Reference Citation Analysis]
103 Spring MD, Lon C, Sok S, Sea D, Wojnarski M, Chann S, Kuntawunginn W, Kheang Heng T, Nou S, Arsanok M, Sriwichai S, Vanachayangkul P, Lin JT, Manning JE, Jongsakul K, Pichyangkul S, Satharath P, Smith PL, Dysoley L, Saunders DL, Waters NC. Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with Plasmodium vivax. Am J Trop Med Hyg 2020;103:756-9. [PMID: 32394887 DOI: 10.4269/ajtmh.20-0061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
104 Ximenez JPB, de Andrade JM, Marques MP, Coelho EB, Suarez-Kurtz G, Lanchote VL. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. BMC Pharmacol Toxicol 2019;20:81. [PMID: 31852530 DOI: 10.1186/s40360-019-0358-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
105 Wang Y, Wang C, Wang S, Zhou Q, Dai D, Shi J, Xu X, Luo Q. Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. Front Pharmacol 2020;11:53. [PMID: 32116727 DOI: 10.3389/fphar.2020.00053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
106 Brasil LW, Rodrigues-Soares F, Santoro AB, Almeida ACG, Kühn A, Ramasawmy R, Lacerda MVG, Monteiro WM, Suarez-Kurtz G. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. Malar J 2018;17:57. [PMID: 29390987 DOI: 10.1186/s12936-017-2139-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
107 Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg 2020;103:1094-9. [PMID: 32524950 DOI: 10.4269/ajtmh.20-0186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
108 Bousman CA, Forbes M, Jayaram M, Eyre H, Reynolds CF, Berk M, Hopwood M, Ng C. Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry 2017;17:60. [PMID: 28178974 DOI: 10.1186/s12888-017-1230-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 8.6] [Reference Citation Analysis]
109 Smith DM, Weitzel KW, Elsey AR, Langaee T, Gong Y, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, Johnson JA, Cavallari LH. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med 2019;21:1842-50. [PMID: 30670877 DOI: 10.1038/s41436-018-0431-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
110 Storelli F, Desmeules J, Daali Y. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes. Basic Clin Pharmacol Toxicol 2019;124:170-80. [PMID: 30192434 DOI: 10.1111/bcpt.13124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
111 Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Asl BB, Bishop JR, Burmeister M, Chaumette B, Chen L, Cordner ZA, Deckert J, Degenhardt F, Delisi LE, Folkersen L, Kennedy JL, Klein TE, Mcclay JL, Mcmahon FJ, Musil R, Saccone NL, Sangkuhl K, Stowe RM, Tan E, Tiwari AK, Zai CC, Zai G, Zhang J, Gaedigk A, Müller DJ. Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry 2021;54:5-17. [DOI: 10.1055/a-1288-1061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
112 Beitzke B, Pate DW. A broader view on deriving a reference dose for THC the in foods. Crit Rev Toxicol 2022;:1-28. [PMID: 35174773 DOI: 10.1080/10408444.2021.2008867] [Reference Citation Analysis]
113 Hein DW, Fakis G, Boukouvala S. Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review. Pharmacogenet Genomics 2018;28:238-44. [PMID: 30222709 DOI: 10.1097/FPC.0000000000000350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Bai Y, Chen G, Yang H, Gao K. Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? J Affect Disord 2020;261:259-70. [PMID: 31669925 DOI: 10.1016/j.jad.2019.10.012] [Reference Citation Analysis]
115 Silvino ACR, Kano FS, Costa MA, Fontes CJF, Soares IS, de Brito CFA, Carvalho LH, Sousa TN. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence. Antimicrob Agents Chemother 2020;64:e02056-19. [PMID: 32122891 DOI: 10.1128/AAC.02056-19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
116 Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology 2019;15:831-47. [DOI: 10.1080/17425255.2019.1669560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
117 Naujokaitis D, Asmoniene V, Kadusevicius E. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study. Medicine (Baltimore) 2021;100:e24545. [PMID: 33725937 DOI: 10.1097/MD.0000000000024545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Gaedigk A, Twist GP, Farrow EG, Lowry JA, Soden SE, Miller NA. In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report. Pharmacogenomics 2017;18:427-31. [PMID: 28290770 DOI: 10.2217/pgs-2016-0192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
119 Zhou Y, Lauschke VM. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. Hum Genet 2021. [PMID: 34652573 DOI: 10.1007/s00439-021-02385-x] [Reference Citation Analysis]
120 Fulton CR, Zang Y, Desta Z, Rosenman MB, Holmes AM, Decker BS, Zhang Y, T Callaghan J, Pratt VM, Levy KD, Gufford BT, Dexter PR, Skaar TC, Eadon MT. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. Pharmacogenomics 2019;20:397-408. [PMID: 30784356 DOI: 10.2217/pgs-2018-0205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
121 Meloche M, Khazaka M, Kassem I, Barhdadi A, Dubé MP, de Denus S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. Br J Clin Pharmacol 2020;86:1015-33. [PMID: 32090368 DOI: 10.1111/bcp.14247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
122 Gaedigk A, Dinh JC, Jeong H, Prasad B, Leeder JS. Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. J Pers Med 2018;8:E15. [PMID: 29673183 DOI: 10.3390/jpm8020015] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 16.8] [Reference Citation Analysis]
123 Drögemöller BI, Wright GEB, Shih J, Monzon JG, Gelmon KA, Ross CJD, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res Treat 2019;173:521-32. [PMID: 30411242 DOI: 10.1007/s10549-018-5027-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
124 Herbert D, Neves-Pereira M, Baidya R, Cheema S, Groleau S, Shahmirian A, Tiwari AK, Zai CC, King N, Müller DJ, Kennedy JL. Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study. J Psychiatr Res 2018;96:265-72. [PMID: 29301639 DOI: 10.1016/j.jpsychires.2017.09.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
125 Myers MF, Zhang X, McLaughlin B, Kissell D, Perry CL, Veerkamp M, Zhang K, Holm IA, Prows CA. Prior opioid exposure influences parents' sharing of their children's CYP2D6 research results. Pharmacogenomics 2017;18:1199-213. [PMID: 28745549 DOI: 10.2217/pgs-2017-0091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Gutiérrez Rico EM, Kikuchi A, Saito T, Kumondai M, Hishinuma E, Kaneko A, Chan CW, Gitaka J, Nakayoshi T, Oda A, Saito S, Hirasawa N, Hiratsuka M. CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity. Drug Metab Pharmacokinet 2020;35:89-101. [PMID: 32037159 DOI: 10.1016/j.dmpk.2019.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Swadi AA, Mohammad BI, Hadi NR, Al-Aubaidy HA. Correlation of CYP2D6 allelic polymorphism to outcome of acute coronary syndrome in mid-Euphrates Iraqi patients on metoprolol therapy. Gene 2019;703:112-9. [PMID: 30965129 DOI: 10.1016/j.gene.2019.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
128 Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes (Basel) 2020;11:E1295. [PMID: 33143137 DOI: 10.3390/genes11111295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
129 Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther 2017;102:688-700. [PMID: 28378927 DOI: 10.1002/cpt.690] [Cited by in Crossref: 233] [Cited by in F6Publishing: 203] [Article Influence: 46.6] [Reference Citation Analysis]
130 Carrão DB, Habenchus MD, de Albuquerque NCP, da Silva RM, Lopes NP, de Oliveira ARM. In vitro inhibition of human CYP2D6 by the chiral pesticide fipronil and its metabolite fipronil sulfone: Prediction of pesticide-drug interactions. Toxicol Lett 2019;313:196-204. [PMID: 31278966 DOI: 10.1016/j.toxlet.2019.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
131 Austin-Zimmerman I, Wronska M, Wang B, Irizar H, Thygesen JH, Bhat A, Denaxas S, Fatemifar G, Finan C, Harju-Seppänen J, Giannakopoulou O, Kuchenbaecker K, Zartaloudi E, McQuillin A, Bramon E. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Genes (Basel) 2021;12:1758. [PMID: 34828364 DOI: 10.3390/genes12111758] [Reference Citation Analysis]
132 Jorge-Aarón RM, Rodrigo RC, Esther MR. Endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment. Pharmacogenomics 2020;21:929-43. [PMID: 32808577 DOI: 10.2217/pgs-2020-0061] [Reference Citation Analysis]
133 Dalton R, Lee SB, Claw KG, Prasad B, Phillips BR, Shen DD, Wong LH, Fade M, McDonald MG, Dunham MJ, Fowler DM, Rettie AE, Schuetz E, Thornton TA, Nickerson DA, Gaedigk A, Thummel KE, Woodahl EL. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity. Clin Transl Sci 2020;13:147-56. [PMID: 31536170 DOI: 10.1111/cts.12695] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
134 Dunham WC, Weinger MB, Slagle J, Pretorius M, Shah AS, Absi TS, Shotwell MS, Beller M, Thomas E, Vnencak-Jones CL, Freundlich RE, Wanderer JP, Sandberg WS, Kertai MD. CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study. J Cardiothorac Vasc Anesth 2020;34:20-8. [PMID: 31606278 DOI: 10.1053/j.jvca.2019.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Jarvis JP, Peter AP, Shaman JA. Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry. Front Psychiatry 2019;10:432. [PMID: 31281270 DOI: 10.3389/fpsyt.2019.00432] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
136 Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics 2020;12:E1200. [PMID: 33322314 DOI: 10.3390/pharmaceutics12121200] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Bothos E, Ntoumou E, Kelaidoni K, Roukas D, Drakoulis N, Papasavva M, Karakostis FA, Moulos P, Karakostis K. Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS). J Transl Med 2021;19:151. [PMID: 33858454 DOI: 10.1186/s12967-021-02816-3] [Reference Citation Analysis]
138 Mauleekoonphairoj J, Chamnanphon M, Khongphatthanayothin A, Sutjaporn B, Wandee P, Poovorawan Y, Nademanee K, Pongpanich M, Chariyavilaskul P. Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation. Sci Rep 2020;10:18969. [PMID: 33144648 DOI: 10.1038/s41598-020-76085-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
139 Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry 2021;:1-68. [PMID: 33977870 DOI: 10.1080/15622975.2021.1878427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
140 Dagenais-Beaulé V. Risperidone is not only a prodrug: psychosis induced by medication switch from risperidone to paliperidone - a case report. Eur J Hosp Pharm 2021:ejhpharm-2021-002901. [PMID: 34785566 DOI: 10.1136/ejhpharm-2021-002901] [Reference Citation Analysis]
141 Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Clin Pharmacokinet 2021. [PMID: 34125422 DOI: 10.1007/s40262-021-01041-x] [Reference Citation Analysis]
142 Saiz-Rodríguez M, Ochoa D, Román M, Zubiaur P, Koller D, Mejía G, Abad-Santos F. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. Pharmacogenomics 2020;21:663-75. [PMID: 32538291 DOI: 10.2217/pgs-2020-0026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 White CM. Inflammation Suppresses Patients' Ability to Metabolize Cytochrome P450 Substrate Drugs. Ann Pharmacother 2021;:10600280211047864. [PMID: 34590872 DOI: 10.1177/10600280211047864] [Reference Citation Analysis]
144 Reis SS, Carvalho AS, Fernandes R. Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms. Medicina (Kaunas) 2019;55:E344. [PMID: 31284530 DOI: 10.3390/medicina55070344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Spring MD, Sousa JC, Li Q, Darko CA, Morrison MN, Marcsisin SR, Mills KT, Potter BM, Paolino KM, Twomey PS, Moon JE, Tosh DM, Cicatelli SB, Froude JW, Pybus BS, Oliver TG, McCarthy WF, Waters NC, Smith PL, Reichard GA, Bennett JW. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population. J Infect Dis 2019;220:1761-70. [PMID: 31549155 DOI: 10.1093/infdis/jiz386] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
146 Fonseca DJ, Morel A, Llinás-Caballero K, Bolívar-Salazar D, Laissue P. Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype. Pharmgenomics Pers Med 2021;14:287-99. [PMID: 33688237 DOI: 10.2147/PGPM.S289869] [Reference Citation Analysis]
147 Bank PCD, Swen JJ, Guchelaar HJ. Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. BMC Med 2019;17:110. [PMID: 31196067 DOI: 10.1186/s12916-019-1342-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
148 Fung M, Xue X, Szilagyi A. Estimating Lactase Nonpersistence Distributions in the Multi-Ethnic Canadian Demographic: A Population-Based Study. J Can Assoc Gastroenterol 2020;3:103-10. [PMID: 32395684 DOI: 10.1093/jcag/gwy068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
149 Yu CY, Ang GY, Subramaniam V, Johari James R, Ahmad A, Abdul Rahman T, Mohd Nor F, Shaari SA, Teh LK, Salleh MZ. Inference of the Genetic Polymorphisms of CYP2D6 in Six Subtribes of the Malaysian Orang Asli from Whole-Genome Sequencing Data. Genet Test Mol Biomarkers 2017;21:409-15. [PMID: 28525288 DOI: 10.1089/gtmb.2016.0235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
150 Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry 2021;78:270-80. [PMID: 33237321 DOI: 10.1001/jamapsychiatry.2020.3643] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
151 McClay JL. Epigenetic regulation of drug metabolism in aging. Aging (Albany NY) 2021;13:16898-9. [PMID: 34251355 DOI: 10.18632/aging.203312] [Reference Citation Analysis]
152 Chaudhry M, Alessandrini M, Rademan J, Dodgen TM, Steffens FE, van Zyl DG, Gaedigk A, Pepper MS. Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics 2017;18:433-43. [PMID: 28350251 DOI: 10.2217/pgs-2016-0185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
153 Jeiziner C, Suter K, Wernli U, Barbarino JM, Gong L, Whirl-Carrillo M, Klein TE, Szucs TD, Hersberger KE, Meyer Zu Schwabedissen HE. Pharmacogenetic information in Swiss drug labels - a systematic analysis. Pharmacogenomics J 2021;21:423-34. [PMID: 33070160 DOI: 10.1038/s41397-020-00195-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
154 Neyshaburinezhad N, Ghasim H, Rouini M, Daali Y, Ardakani YH. Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data. J Pers Med 2021;11:804. [PMID: 34442448 DOI: 10.3390/jpm11080804] [Reference Citation Analysis]
155 Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, Rodríguez-Antona C. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet Med 2018;20:622-9. [PMID: 29261188 DOI: 10.1038/gim.2017.156] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
156 Dong Y, Huang H, Deng Y, Xu Y, Chen M, Liu Y, Zhang C. Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China. Malar J 2021;20:448. [PMID: 34823523 DOI: 10.1186/s12936-021-03988-5] [Reference Citation Analysis]
157 Modak AS. Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need. J Breath Res 2017;12:017101. [PMID: 28920579 DOI: 10.1088/1752-7163/aa8d2e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
158 Silva AR, Dinis-oliveira RJ. Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects. Drug Metabolism Reviews 2020;52:258-82. [DOI: 10.1080/03602532.2020.1758712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Battise D, Boland CL, Nuzum DS. Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet. Ann Pharmacother 2019;53:402-12. [DOI: 10.1177/1060028018813575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Manoharan A, Shewade DG, Ravindranath PA, Rajkumar RP, Ramprasad VL, Adithan S, Damodaran SE. Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele. Pharmacogenomics 2019;20:719-29. [PMID: 31368850 DOI: 10.2217/pgs-2019-0049] [Reference Citation Analysis]
161 Vassiliou D, Sardh E, Harper P, Simon AR, Clausen VA, Najafian N, Robbie GJ, Agarwal S. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. Clin Pharmacol Ther 2021;110:1250-60. [PMID: 34510420 DOI: 10.1002/cpt.2419] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 He W, Grassmann F, Eriksson M, Eliasson E, Margolin S, Thorén L, Hall P, Czene K. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. J Clin Oncol 2020;38:548-57. [PMID: 31800347 DOI: 10.1200/JCO.19.01535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
163 Fernandes MR, Rodrigues JCG, Maroñas O, Latorre-Pellicer A, Cruz R, Guerreiro JF, Burbano RMR, de Assumpção PP, Ribeiro-Dos-Santos A, Dos Santos SEB, Carracedo A, Dos Santos NPC. Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon. Pharmgenomics Pers Med 2021;14:117-33. [PMID: 33519226 DOI: 10.2147/PGPM.S274741] [Reference Citation Analysis]
164 Abouir K, Samer CF, Gloor Y, Desmeules JA, Daali Y. Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends. Front Pharmacol 2021;12:708299. [PMID: 34776945 DOI: 10.3389/fphar.2021.708299] [Reference Citation Analysis]
165 Montané Jaime LK, Paul J, Lalla A, Legall G, Gaedigk A. Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics 2018;19:197-212. [PMID: 29327975 DOI: 10.2217/pgs-2017-0142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
166 Nefic H. The Genetic Variation of CYP2D6 Gene in the Bosnian Population. Med Arch 2018;72:396-400. [PMID: 30814768 DOI: 10.5455/medarh.2018.72.396-400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Hongkaew Y, Gaedigk A, Wilffert B, Ngamsamut N, Kittitharaphan W, Limsila P, Sukasem C. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Sci Rep 2021;11:4158. [PMID: 33603025 DOI: 10.1038/s41598-021-83570-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Finegan E, Chipika RH, Li Hi Shing S, Hardiman O, Bede P. Pathological Crying and Laughing in Motor Neuron Disease: Pathobiology, Screening, Intervention. Front Neurol 2019;10:260. [PMID: 30949121 DOI: 10.3389/fneur.2019.00260] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
169 Daripally S, Peddi K. Polymorphic variants of drug-metabolizing enzymes alter the risk and survival of oral cancer patients. 3 Biotech 2020;10:529. [PMID: 33214976 DOI: 10.1007/s13205-020-02526-5] [Reference Citation Analysis]
170 Li Q, Wu YE, Wang K, Shi HY, Zhou Y, Zheng Y, Hao GX, Yang YL, Su LQ, Wang WQ, Yang XM, Zhao W. Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug. Front Pharmacol 2021;12:657287. [PMID: 34295246 DOI: 10.3389/fphar.2021.657287] [Reference Citation Analysis]
171 Klopp-Schulze L, Joerger M, Wicha SG, Ter Heine R, Csajka C, Parra-Guillen ZP, Kloft C. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clin Pharmacokinet 2018;57:229-42. [PMID: 28540639 DOI: 10.1007/s40262-017-0555-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
172 Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ. Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects. Arch Pharm Res 2020;43:976-81. [PMID: 32661920 DOI: 10.1007/s12272-020-01250-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
173 Wendt FR, Pathak G, Sajantila A, Chakraborty R, Budowle B. Global genetic variation of select opiate metabolism genes in self-reported healthy individuals. Pharmacogenomics J 2018;18:281-94. [PMID: 28398354 DOI: 10.1038/tpj.2017.13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
174 Charnaud S, Munro JE, Semenec L, Mazhari R, Brewster J, Bourke C, Ruybal-Pesántez S, James R, Lautu-Gumal D, Karunajeewa H, Mueller I, Bahlo M. PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus. Commun Biol 2022;5:168. [PMID: 35217695 DOI: 10.1038/s42003-022-03102-8] [Reference Citation Analysis]
175 Popovici J, Tebben K, Witkowski B, Serre D. Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters. Int J Parasitol Drugs Drug Resist 2021;15:36-42. [PMID: 33529838 DOI: 10.1016/j.ijpddr.2020.12.004] [Reference Citation Analysis]
176 Huang W, Nakano M, Sager J, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. Drug Metab Dispos 2017;45:1156-65. [PMID: 28860113 DOI: 10.1124/dmd.117.076455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
177 Tang Girdwood SC, Rossow KM, Van Driest SL, Ramsey LB. Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians. Pediatr Res 2021. [PMID: 33824446 DOI: 10.1038/s41390-021-01499-2] [Reference Citation Analysis]
178 Canut MI, Villa O, Kudsieh B, Mattlin H, Banchs I, González JR, Armengol L, Casaroli-Marano RP. MLIP genotype as a predictor of pharmacological response in primary open-angle glaucoma and ocular hypertension. Sci Rep 2021;11:1583. [PMID: 33452295 DOI: 10.1038/s41598-020-80954-2] [Reference Citation Analysis]
179 Yang Y, Botton MR, Scott ER, Scott SA. Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing. Pharmacogenomics 2017;18:673-85. [PMID: 28470112 DOI: 10.2217/pgs-2017-0033] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
180 Viviani R, Messina I, Bosch JE, Dommes L, Paul A, Schneider KL, Scholl C, Stingl JC. Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity. Transl Psychiatry 2020;10:338. [PMID: 33024081 DOI: 10.1038/s41398-020-01020-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
181 Meloche M, Leclair G, Jutras M, Oussaïd E, Gaulin MJ, Mongrain I, Busseuil D, Tardif JC, Dubé MP, de Denus S. Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study. Clin Transl Sci 2022. [PMID: 35122397 DOI: 10.1111/cts.13230] [Reference Citation Analysis]
182 Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 2018;41:921-30. [PMID: 30191460 DOI: 10.1007/s12272-018-1075-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
183 Ruaño G, Robinson S, Holford T, Mehendru R, Baker S, Tortora J, Goethe JW. Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints. Contemp Clin Trials 2020;89:105910. [PMID: 31838256 DOI: 10.1016/j.cct.2019.105910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
184 Ing Lorenzini K, Desmeules J, Rollason V, Bertin S, Besson M, Daali Y, Samer CF. CYP450 Genotype-Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting. Front Pharmacol 2021;12:730637. [PMID: 34512355 DOI: 10.3389/fphar.2021.730637] [Reference Citation Analysis]
185 Ivashchenko DV, Khoang SZ, Makhmudova BV, Buromskaya NI, Shimanov PV, Deitch RV, Akmalova KA, Shuev GN, Dorina IV, Nastovich MI, Shagovenko EN, Grishina EA, Savchenko LM, Shevchenko YS, Sychev DA. Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. Drug Metab Pers Ther 2020:/j/dmdi. [PMID: 32827391 DOI: 10.1515/dmpt-2020-0102] [Reference Citation Analysis]
186 Maggo SDS, Sycamore KLV, Miller AL, Kennedy MA. The Three Ps: Psychiatry, Pharmacy, and Pharmacogenomics, a Brief Report From New Zealand. Front Psychiatry 2019;10:690. [PMID: 31616328 DOI: 10.3389/fpsyt.2019.00690] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
187 Lemieux Perreault L, Zaïd N, Cameron M, Mongrain I, Dubé M. Pharmacogenetic content of commercial genome-wide genotyping arrays. Pharmacogenomics 2018;19:1159-67. [DOI: 10.2217/pgs-2017-0129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
188 Lu S, Nand RA, Yang JS, Chen G, Gross AS. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. Eur J Clin Pharmacol 2018;74:285-96. [PMID: 29181698 DOI: 10.1007/s00228-017-2375-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
189 Storelli F, Matthey A, Lenglet S, Thomas A, Desmeules J, Daali Y. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions. Clin Pharmacol Ther 2018;104:148-57. [PMID: 28940476 DOI: 10.1002/cpt.889] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
190 Ferreira MU, Nobrega de Sousa T, Rangel GW, Johansen IC, Corder RM, Ladeia-Andrade S, Gil JP. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions. Int J Parasitol Drugs Drug Resist 2021;15:9-24. [PMID: 33360105 DOI: 10.1016/j.ijpddr.2020.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
191 Darney K, Lautz LS, Béchaux C, Wiecek W, Testai E, Amzal B, Dorne JLCM. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs. Environ Int 2021;156:106760. [PMID: 34256299 DOI: 10.1016/j.envint.2021.106760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther 2019;106:94-102. [PMID: 30801677 DOI: 10.1002/cpt.1409] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 19.0] [Reference Citation Analysis]
193 Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, Truong TM, van Wijk XMR, Yeo KJ, Malec M, Ratain MJ, O'Donnell PH. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Oncologist 2021;26:e2042-52. [PMID: 34423496 DOI: 10.1002/onco.13953] [Reference Citation Analysis]
194 Gaedigk A, Turner A, Everts RE, Scott SA, Aggarwal P, Broeckel U, McMillin GA, Melis R, Boone EC, Pratt VM, Kalman LV. Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project. J Mol Diagn 2019;21:1034-52. [PMID: 31401124 DOI: 10.1016/j.jmoldx.2019.06.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
195 Mwaiswelo RO, Ngasala B, Msolo D, Kweka E, Mmbando BP, Mårtensson A. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania. Malar J 2022;21. [DOI: 10.1186/s12936-022-04100-1] [Reference Citation Analysis]
196 Namerow LB, Walker SA, Loftus M, Bishop JR, Ruaño G, Malik S. Pharmacogenomics: an Update for Child and Adolescent Psychiatry. Curr Psychiatry Rep 2020;22. [DOI: 10.1007/s11920-020-01145-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
197 Cui Y, Yan H, Su Y, Wang L, Lu T, Zhang D, Yue W. CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People. Front Pharmacol 2020;11:936. [PMID: 32848719 DOI: 10.3389/fphar.2020.00936] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
198 Cuéllar-Barboza AB, McElroy SL, Veldic M, Singh B, Kung S, Romo-Nava F, Nunez NA, Cabello-Arreola A, Coombes BJ, Prieto M, Betcher HK, Moore KM, Winham SJ, Biernacka JM, Frye MA. Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. Int J Bipolar Disord 2020;8:23. [PMID: 32632502 DOI: 10.1186/s40345-020-00184-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Zhang L, Brown SJ, Shan Y, Lee AM, Allen JD, Eum S, de Leon J, Bishop JR. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis. Pharmacotherapy 2020;40:632-47. [PMID: 32519344 DOI: 10.1002/phar.2434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
200 Hoehe MR, Morris-Rosendahl DJ. The role of genetics and genomics in clinical psychiatry. Dialogues Clin Neurosci 2018;20:169-77. [PMID: 30581286 [PMID: 30581286 DOI: 10.31887/dcns.2018.20.3/mhoehe] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
201 Chamnanphon M, Gaedigk A, Vanwong N, Nuntamool N, Hongkaew Y, Puangpetch A, Sukasem C. CYP2D6 genotype analysis of a Thai population: platform comparison. Pharmacogenomics 2018;19:947-60. [DOI: 10.2217/pgs-2018-0075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
202 Rodriguez Cairoli F, Appiani F, Sambade JM, Comandé D, Camacho Arteaga L, Ciapponi A. Efficacy and safety of opioid therapy guided by pharmacogenetics: a systematic review. Pharmacogenomics 2021;22:573-86. [PMID: 34013775 DOI: 10.2217/pgs-2021-0021] [Reference Citation Analysis]
203 Budowle B, Schmedes SE, Wendt FR. Increasing the reach of forensic genetics with massively parallel sequencing. Forensic Sci Med Pathol 2017;13:342-9. [DOI: 10.1007/s12024-017-9882-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
204 Cook-Sather SD, Adamson PC, Li J, Hakonarson H. CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine! Anesthesiology 2016;125:1085-7. [PMID: 27763886 DOI: 10.1097/ALN.0000000000001399] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
205 Gazzaz M, Kinzig M, Schaeffeler E, Jübner M, Hsin C, Li X, Taubert M, Trueck C, Iltgen-breburda J, Kraus D, Queckenberg C, Stoffel M, Schwab M, Sörgel F, Fuhr U. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What? Clin Pharmacol Ther 2018;104:1249-59. [DOI: 10.1002/cpt.1083] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
206 Li D, Peng L, Xing S, He C, Jin T. Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China. BMC Genom Data 2021;22:51. [PMID: 34798807 DOI: 10.1186/s12863-021-00999-8] [Reference Citation Analysis]
207 He L, Chen S, Li J, Xie X, Huang L, Kuang Y, Xu K, Huang W, Zhao Y, Yang G, Guo C. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese. Clin Exp Pharmacol Physiol 2020;47:1659-63. [PMID: 32469422 DOI: 10.1111/1440-1681.13357] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
208 Don CG, Smieško M. Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function. PLoS One 2018;13:e0202534. [PMID: 30133539 DOI: 10.1371/journal.pone.0202534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
209 Kim KA, Park IB, Park JY. Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans. Eur J Clin Pharmacol 2018;74:1281-9. [PMID: 29947950 DOI: 10.1007/s00228-018-2501-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
210 Marcos-vadillo E, Carrascal-laso L, Ramos-gallego I, Gaedigk A, García-berrocal B, Mayor-toranzo E, Sevillano-jiménez A, Sánchez A, Isidoro-garcía M, Franco-martín M. Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New CYP2D6 Genotype. Front Psychiatry 2022;12:830608. [DOI: 10.3389/fpsyt.2021.830608] [Reference Citation Analysis]
211 Reisberg S, Krebs K, Lepamets M, Kals M, Mägi R, Metsalu K, Lauschke VM, Vilo J, Milani L. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genet Med 2019;21:1345-54. [PMID: 30327539 DOI: 10.1038/s41436-018-0337-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
212 Haslemo T, Eliasson E, Jukić MM, Ingelman-Sundberg M, Molden E. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. Br J Clin Pharmacol 2019;85:194-201. [PMID: 30312494 DOI: 10.1111/bcp.13788] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
213 Alali M, Ismail Al-khalil W, Rijjal S, Al-salhi L, Saifo M, Youssef LA. Frequencies of CYP2D6 genetic polymorphisms in Arab populations. Hum Genomics 2022;16. [DOI: 10.1186/s40246-022-00378-z] [Reference Citation Analysis]
214 Ning M, Duarte JD, Rubin LH, Jeong H. CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue. Clin Pharmacol Ther 2018;104:974-82. [PMID: 29349771 DOI: 10.1002/cpt.1032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
215 Wendt FR, Sajantila A, Budowle B. Predicted activity of UGT2B7, ABCB1, OPRM1, and COMT using full-gene haplotypes and their association with the CYP2D6-inferred metabolizer phenotype. Forensic Science International: Genetics 2018;33:48-58. [DOI: 10.1016/j.fsigen.2017.11.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
216 Don CG, Smieško M. Out‐compute drug side effects: Focus on cytochrome P450 2D6 modeling. WIREs Comput Mol Sci 2018;8. [DOI: 10.1002/wcms.1366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez J, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 2017;102:213-8. [PMID: 28002639 DOI: 10.1002/cpt.598] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 16.6] [Reference Citation Analysis]
218 Mills RA, Eichmeyer JN, Williams LM, Muskett JA, Schmidlen TJ, Maloney KA, Lemke AA. Patient Care Situations Benefiting from Pharmacogenomic Testing. Curr Genet Med Rep 2018;6:43-51. [DOI: 10.1007/s40142-018-0136-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
219 Tong H, Phan NVT, Nguyen TT, Nguyen DV, Vo NS, Le L. Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions. Pharmgenomics Pers Med 2021;14:61-75. [PMID: 33469342 DOI: 10.2147/PGPM.S290781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
220 Brown JT, Schneiderhan M, Eum S, Bishop JR. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics 2017;18:601-5. [PMID: 28470111 DOI: 10.2217/pgs-2017-0015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
221 Huang H, Dong Y, Xu Y, Deng Y, Zhang C, Liu S, Chen M, Liu Y. The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China. Malar J 2021;20:160. [PMID: 33743705 DOI: 10.1186/s12936-021-03685-3] [Reference Citation Analysis]
222 Kamenski G, Ayazseven S, Berndt A, Fink W, Kamenski L, Zehetmayer S, Pühringer H. Clinical Relevance of CYP2D6 Polymorphisms in Patients of an Austrian Medical Practice: A Family Practice-Based Observational Study. Drugs Real World Outcomes 2020;7:63-73. [PMID: 31863305 DOI: 10.1007/s40801-019-00177-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Kishi T, Ikuta T, Sakuma K, Okuya M, Iwata N. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. J Psychiatr Res 2021;138:444-52. [PMID: 33964682 DOI: 10.1016/j.jpsychires.2021.04.032] [Reference Citation Analysis]
224 Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 2020;43:1207-13. [PMID: 33247397 DOI: 10.1007/s12272-020-01293-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
225 de Leon J. Have we successfully implemented CYP2D6 genotyping in psychiatry? Expert Opinion on Drug Metabolism & Toxicology 2017;13:1201-3. [DOI: 10.1080/17425255.2017.1406920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]